Candel Therapeutics, Inc. cash flow to debt ratio of -2.01K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Candel Therapeutics, Inc.'s free cash flow has decreased 43.86% from $-27.04M last year to $-38.90M, signaling decreasing performance

Candel Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Candel Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.20 last year to 0.01 today, signaling strengthened financials

Candel Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Candel Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Candel Therapeutics, Inc. has insufficient data to evaluate this check.

Candel Therapeutics, Inc.'s short-term assets of $119.73M exceed its short-term liabilities of $9.00M

Candel Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Candel Therapeutics, Inc.'s return on equity of -60.42%, is lower than 15.00%, indicating bad performance

Candel Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Candel Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Candel Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Candel Therapeutics, Inc. has negative free cash flow, indicating cash burn

Candel Therapeutics, Inc.'s yearly earnings has increased -30.80% since last year from $-55.18M to $-38.18M, signaling increasing performance

Candel Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -28.89% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Candel Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Candel Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Candel Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Candel Therapeutics, Inc. has insufficient data to evaluate this check.

Candel Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Candel Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Candel Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Candel Therapeutics, Inc. has insufficient data to evaluate this check.

Candel Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Candel Therapeutics, Inc. has a price-to-book ratio of 4.42x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Candel Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue